Abstract: The present disclosure relates to an anti-inflammatory peptide including at least one selected from the group consisting of the amino acid sequences of SEQ ID NOS: 1 to 63 and modifications thereof, an anti-inflammatory composition comprising the same, and a pharmaceutical composition for preventing or treating inflammatory diseases. An anti-inflammatory peptide according to an embodiment of the present disclosure has no cytotoxicity, and has an effect of inhibiting the activation of mitochondrial antiviral signaling protein (MAVS), immune/inflammatory activation mechanism and the expression or activity of inflammatory cytokines and inflammasomes. Therefore, the peptide can be applied to an anti-inflammatory composition or a composition for treating inflammatory diseases.

Abstract: Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically.

Abstract: Disclosed is a method for the treatment and/or diagnosis of cancer, using bacterial cell-derived microvesicles, which is highly effective in cancer therapy with a significant reduction in side effects. Also, a method is provided for delivering of a drug therapeutic or diagnostic for a disease, using bacterial cell-derived microvesicles loaded with the drug, thereby treating and diagnosing the disease effectively and specifically.